CD33 and neoplasm: The first BiTE designed and employed for AML treatment was AMG330, which targets the antigens CD33 on tumor cells and CD3 on T cells; preliminary data showed important in vitro antileukemic activity and particularly the capacity of avoiding key mechanisms for tumor resistance, such as CD33 downregulation [142].